Vela Diagnostics Rolled Out Sentosa® Next Generation Sequencing Workflow at Institute Gustave Roussy for Routine Diagnosis

By Vela Diagnostics

November 25, 2015

 

Genomeweb/ Germany (November 25, 2015) – Vela Diagnostics is pleased to announce that Institute Gustave Roussy, the leading Comprehensive Cancer Centre in Europe, has started to use Vela’s Next Generation Sequencing (NGS) workflow in routine diagnosis for the detection of mutations relevant to colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and Melanoma.

 

The Sentosa® NGS workflow, launched in 2014, is the first CE-IVD system on the market, which offers a complete solution from sample to result, providing instruments, reagents, consumables and bioinformatics support. The Sentosa® NGS workflow automates sample extraction, library and template preparation, sequencing as well as providing data analysis and result reporting. Sentosa® Oncology Panels are specifically designed to target clinical relevant hotspot mutations. Sentosa® SQ Reporter automatically reports with a quality score. Through the Sentosa® Link, sample traceability is maintained throughout the entire workflow, with seamless LIMS connectivity.

 

“We are very happy to work with a prestigious institute such as Gustave Roussy,” said Dr. Andreas Görtz, Managing Director of Vela Diagnostics Europe. Moving forward, Vela will have a number of collaborations with Gustave Roussy on solid and liquid tumour diagnosis using Vela’s complete NGS solution. With features such as automation, short turn-around time and clinically relevant targets, Sentosa® NGS workflow is suited for routine diagnostic needs. Developed with the routine laboratory work in mind, testing using Sentosa® NGS workflow requires minimal sample input, space and hands-on time. “Sentosa® NGS Oncology panels cover targets required by oncologists for clinical decision-making,” said Andreas Görtz. 

 

Thus far, Vela has launched four NGS Oncology panels – Melanoma, NSCLC, CRC, Thyroid, and one NGS Virology panel – HCV Genotyping (RUO). Pipeline includes Leukemia panel and HIV Genotyping, to be launched in 2016.

 

To learn more about Sentosa NGS workflow and test menu, visit http://www.veladx.com/products.html#ngs

To inquire more on product performance data and technical presentation, please contact Global Product Management, gpm@veladx.com

Go back